Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.

Satoshi OkaTakahiko KaiKatsuomi HoshinoKazunori WatanabeJun NakamuraMakoto AbeAkinori Watanabe

Published in: BMC cardiovascular disorders (2021)

The positive effects of empagliflozin on LV dysfunction were more remarkable in early than in advanced DMCMP. Early intervention of SGLT2i for DMCMP may be preferable.

Keyphrases

randomized controlled trial
heart failure
oxidative stress
type diabetes
metabolic syndrome
atrial fibrillation
weight loss
glycemic control